Alto Neuroscience
ANRO----
Alto Neuroscience (ANRO)
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Alto Neuroscience Analyst Rating
View MoreForecast & Rating
Jul 13, 2026Price forecast
$35.1331.55%
Forecast & RatingStrong buy
12analysts
- Strong buy91.67%
- Buy0.00%
- Hold8.33%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Jul 15 at 03:12 AM
Alto Neuroscience Raises Capital to Advance ALTO-207
- rttnews · Jul 15 at 02:55 AM
Biotech Stocks Hit 52-Week Highs - TOI, IKT, ANRO, ELV, PRVA
- TradingView · Jul 14 at 05:13 AM
Alto Neuroscience Launches $93.9M Stock Offering at $26.48 in BofA-Led Underwriting
- Tip Ranks · Jul 13 at 07:51 AM
Alto Neuroscience Highlights Strong Cash, Expands ALTO-207 Trials
- PUBT · Jul 13 at 06:40 AM
Alto Neuroscience estimates June 30 cash, equivalents and restricted cash at $244.2 million
- StockTitan · Jul 12 at 10:47 PM
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock | ANRO Stock News
